Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 2Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Lung Neoplasms 1

Interventions

Paclitaxel 9Carboplatin 8Bevacizumab 8fluzoparib 5olaparib 3Topotecan 3Gemcitabine 3liposomal doxorubicin 2famitinib 2apatinib 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Indocyanine Green 2Drug Therapy 2Cisplatin 2trametinib 1senaparib 1pembrolizumab 1niraparib 1montelukast 1irinotecan sucrosofate 1fludarabine 1durvalumab 1dalpiciclib 1dabrafenib 1ceralasertib 1anlotinib 1aldesleukin 1Ultrasonography, Doppler 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Ovarian Neoplasms × Pafolacianine × Clear all
NCT07469202 2026-03-13

CYTALUX Dose Extension Study

On Target Laboratories, LLC

Phase 4 Not yet recruiting
106 enrolled
GynecologicThoracic

Lung Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡